

Key Operational Highlights

IDT Maintaining Profitability, Strong Cash Balance

- H1 FY`22: Revenue year-on-year increase of 74% to \$8.56 million, EBITDA of \$1.97 million and \$1.21 million Profit
- H1 FY`22 closing cash balance of \$13.31 million

Sterile Manufacturing Licence Secured From The Therapeutic Goods Administration

- Successfully executed the Letter Agreement with the Australian Government, Department of Health, to bring IDT's cGMP sterile manufacturing facility into a state of readiness
- Sterile manufacturing licence secured from Therapeutic Goods Administration

IDT Manufactures Australia's First cGMP mRNA Drug Product

IDT successfully manufactured the Monash University / Doherty Institute developed mRNA COVID-19 receptor binding domain vaccine drug
product. Australia's first locally developed and manufactured mRNA COVID-19 vaccine candidate

IDT's Sovereign Manufacturing Initiatives

- IDT was unsuccessful (along with all ATM respondents) in its submission to the Australian Government's Approach To Market- Onshore mRNA Manufacturing Capability
- IDT's Modern Manufacturing Initiative (Collaboration and Translation Stream) funding opportunities remain live

Continuing To Execute On The Company's Medicinal Cannabis Manufacturing Plan

- Expanding stability data for flower-in-bottle and oil-in-bottle products
- Advancing a pipeline of new product development opportunities



Key Financial Highlights

Strong cash balance of \$13.31 million

Year-on-year Revenue increase of 74% to \$8.56 million

Positive EBITDA of \$1.97 million achieved for the half year

\$1.21 million Profit for the half year improved by \$8%

0.5¢ Earnings per share

Results support IDT's objective to progress the business to sustainable profitability

Half Year ended 31 December ('\$000)	2021	2020	Variance	
Revenue	8,559	4,911	3,648	74% 🕇
EBITDA	1,974	1,927	47	2% 🕇
NPAT	1,214	1,124	90	8% 🕇
Basic earnings per share	0.5¢	0.5¢		-





Sterile Manufacturing: Australia's First cGMP mRNA Drug Product

- During the Half Year in review IDT engaged with the Therapeutic Goods Administration (TGA) to successfully
 deliver the Sterile Readiness Letter Agreement finalised with the Australian Government, Department of Health
- A Sterile Manufacturing Licence (the Company's first ever sterile licence) has been secured from the TGA
- IDT's flagship sterile manufacturing facility is now being maintained in a state of sterile readiness
- IDT utilised its sterile manufacturing facilities and capabilities to successfully manufacture Australia's first cGMP mRNA COVID-19 vaccine candidate, destined for clinical trials
- The Monash University / Doherty Institute developed mRNA COVID-19 receptor binding domain vaccine is Australia's first locally developed mRNA COVID-19 vaccine candidate

Goal:

IDT's goal is to leverage its existing sterile facilities and capabilities to play a role in Australia's emerging mRNA manufacturing ecosystem and to provide other fee-for-service sterile manufacturing services.



Sovereign Manufacturing

Approach-To-Market Bid Unsuccessful Modern Manufacturing Initiative Bids Remain Live

- IDT put forward its existing and licenced sterile manufacturing facility in support of a submission to the Australian Government's Onshore mRNA Manufacturing Capability: Approach To Market (ATM). The Company's bid was for IDT to deliver a population scale end-to-end mRNA Australian sovereign manufacturing solution
- All ATM submissions (including IDT's) were unsuccessful
- IDT has ongoing support from industry and academia, including The Peter Doherty Institute for Infection and Immunity, Monash University, University of Melbourne and the Australian National University to build an mRNA manufacturing ecosystem in Australia. This support underpins IDT's submissions to the Australian Government's Modern Manufacturing Initiative Collaboration and Translation Stream grants (MMI)
- IDT's MMI Collaboration and Translation Stream opportunities remain live



Medicinal Cannabis

IDT making further progress executing on its Medicinal Cannabis Manufacturing Plan

- IDT continues to progress the cGMP development of a range of proprietary medicinal cannabis active pharmaceutical ingredient and finished dosage form products
- Stability programs ongoing for IDT's cGMP medicinal cannabis flower-in-bottle and oil-in-bottle products. Several
 of these products are now on market with more to follow
- IDT is advancing a series of medicinal cannabis finished dosage form new product development opportunities

Goals:

IDT's goals remain: (i) to provide contract development and manufacturing services to our current and future medicinal cannabis customers; and (ii) to expand our range of IDT proprietary medicinal cannabis products for local and international distribution



IDT Australia Limited

Board of Directors

Mr Alan Fisher Chair

Experienced corporate advisor and public company director with a proven track record of implementing strategies that enhance shareholder value

Mr Hugh Burrill

Pharma pipeline portfolio management and product development (Ex Hospira/Mayne Pharma)

Dr Jane Ryan

Technically qualified in product development with a strong international career. Experience at board and executive level in business development and partnering.

Mr Michael Kotsanis

Over 30 years strategic and operational experience in the global pharmaceutical industry (Acrux CEO, Ex Synthon, Hospira/Mayne Pharma)

Executive Team

Dr David Sparling CEO

More than 20 years of pharma and diagnostics experience in CEO, Director and Corporate/Business Development roles (Ex Agenix Limited, GTG Limited)

Ms Ancila Desai CFO

Over fifteen years of experience in strategic finance, commercial finance, M&A, financial modelling and capital management (Ex Metcash, Toll and Boost Juice)

Mr Paul McDonald Head of Quality and Development

More than 20 years of high quality parenteral product development and manufacturing (Ex Pfizer, Hospira)

Mr Chris Kagiaros Head of People and Culture

Over 20 years in human resource roles including regional leadership positions and 14 years in pharma (Ex CSL, Medibank and Pfizer)



